STC-004 is an oral, highly selective Na V 1.8 inhibitor under development for the treatment of acute and chronic peripheral pain. The phase 1 study, STC-004-CS-001, ...

In February, SiteOne announced positive results from an early-stage study on STC-004, which showed that the drug was safe and well-tolerated at all dose levels while also improving pain tolerance.

The addition of STC-004 is likely to diversify the company’s existing non-opioid pain pipeline. Notably, the mechanism utilized by STC-004 was validated earlier this year when the FDA approved Vertex ...